Literature DB >> 23219269

The immunoproteasome in antigen processing and other immunological functions.

Michael Basler1, Christopher J Kirk, Marcus Groettrup.   

Abstract

Treatment of cells with interferon-γ leads to the replacement of the constitutive catalytic proteasome subunits β1, β2, and β5 by the inducible subunits LMP2 (β1i), MECL-1 (β2i), and LMP7 (β5i), respectively, building the so-called immunoproteasome. The incorporation of these subunits is required for the production of numerous MHC class-I restricted T cell epitopes. Recently, new evidence for an involvement of the immunoproteasome in other facets of the immune response emerged. Investigations of autoimmune diseases in animal models and a genetic predisposition of β5i in human autoimmune disorders suggest a crucial function of the immunoproteasome in proinflammatory diseases. The recent elucidation of the high-resolution structure of the immunoproteasome will facilitate the design of immunoproteasome selective inhibitors for pharmacological intervention.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23219269     DOI: 10.1016/j.coi.2012.11.004

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  100 in total

1.  Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Hugo D Meiring; Lennert Janssen; Jacques J Neefjes; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

2.  Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage.

Authors:  Celia R Berkers; Annemieke de Jong; Karianne G Schuurman; Carsten Linnemann; Jan A J Geenevasen; Ton N M Schumacher; Boris Rodenko; Huib Ovaa
Journal:  J Immunol       Date:  2015-09-23       Impact factor: 5.422

Review 3.  The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors.

Authors:  Daniel E Johnson
Journal:  Endocr Relat Cancer       Date:  2014-03-21       Impact factor: 5.678

4.  Association between LMP2 and LMP7 gene polymorphisms and the risk of gastric cancer: A case-control study.

Authors:  Xiang Ma; Chao Yang; Ran Tang; Zekuan Xu; Zhihong Zhang; Younan Wang; Jingjing Zhang; L I Yang
Journal:  Oncol Lett       Date:  2015-04-27       Impact factor: 2.967

Review 5.  Proteasome Activation as a New Therapeutic Approach To Target Proteotoxic Disorders.

Authors:  Evert Njomen; Jetze J Tepe
Journal:  J Med Chem       Date:  2019-03-14       Impact factor: 7.446

6.  Proteasome or immunoproteasome inhibitors cause apoptosis in human renal tubular epithelial cells under normoxic and hypoxic conditions.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Georgia Antoniadi; Vassilios Liakopoulos; Ioannis Stefanidis
Journal:  Int Urol Nephrol       Date:  2016-02-26       Impact factor: 2.370

7.  LPM7 Inhibitors May Potentially Treat Autoimmune Diseases.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-05-01       Impact factor: 4.345

Review 8.  Recent advances in the neuroimmunology of cell-surface CNS autoantibody syndromes, Alzheimer's disease, traumatic brain injury and schizophrenia.

Authors:  Ed Needham; Michael S Zandi
Journal:  J Neurol       Date:  2014-09-03       Impact factor: 4.849

Review 9.  Ubiquitin-proteasome signaling in lung injury.

Authors:  Natalia D Magnani; Laura A Dada; Jacob I Sznajder
Journal:  Transl Res       Date:  2018-04-23       Impact factor: 7.012

10.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.